Metabolic dysfunction-associated fatty liver disease (MAFLD) as a more accurate name for NAFLD – common aspects of pathogenesis

Česká verzia

Authors: Barbora Nováková
Authors place of work: 4. interní klinika – klinika gastroenterologie a hepatologie 1. LF UK a VFN v Praze
Published in the journal: Čas. Lék. čes. 2022; 161: 65-71
Category: Review Article

Summary

Non-alcoholic fatty liver disease is considered a common hepatic manifestation of metabolic syndrome. With respect to the pathogenesis of liver steatosis and non-alcoholic steatohepatitis, recently a consensus of international experts proposed a change in the name of the disease to metabolic dysfunction-associated fatty liver disease (MAFLD). The new name should not only better reflect the pathogenesis, but also better stratify risks of the patients’ treatment and eliminate stigmatization originating from the presence of the term "alcohol" in the name of the disease. This work also emphasizes the common pathophysiological mechanisms involved in both metabolic syndrome and liver steatosis, such as dyslipidemia, insulin resistance, gut dysbiosis, oxidative stress, genetic, epigenetic and hormonal factors.

Keywords:

Non-coding RNA – Microbiome – Adipokines – metabolic syndrome – NAFLD – NASH – non-alcoholic fatty liver disease – diabetes mellitus type 2 – dyslipidemia – non-alcoholic steatohepatitis – proteome – bile acids

Zdroje

Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2017; 15(1): 11–20.
Alberti KG, Eckel RH, Grundy SM et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120(16): 1640–1645.
Kučera K, Malinovská J, Jenšovský M a kol. Metabolický syndrom v ordinaci praktického lékaře. Praktický lékař 2020; 100(4): 182–185.
Michelotti GA, Machado MV, Diehl AM. NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol 2013; 10(11): 656–665.
Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019; 92: 82–97.
Kunutsor SK, Abbasi A, Adler AI. Gamma-glutamyl transferase and risk of type II diabetes: an updated systematic review and dose-response meta-analysis. Ann Epidemiol 2014; 24(11): 809–816.
Adams L. Body mass index is a stronger predictor of alanine aminotransaminase levels than alcohol consumption. J Gastroenterol Hepatol 2008; 23(7 Pt. 1): 1089–1093
Méndez-Sánchez N, Bugianesi E, Gish RG et al. Global multi-stakeholder endorsement of the MAFLD definition. Lancet Gastroenterol Hepatol 2022; 7(5): 388–390.
Fuchs M, Sanyal AJ. Lipotoxicity in NASH. J Hepatol 2012; 56(1): 291–293.
Šmíd V, Dvořák K, Šedivý P et al. Effect of omega‐3 polyunsaturated fatty acids on lipid metabolism in patients with metabolic syndrome and NAFLD. Hepatol Commun 2022; 6(6): 1336–1349.
Angelico F, Del Ben M, Conti R et al. Insulin resistance, the metabolic syndrome, and nonalcoholic fatty liver disease. J Clin Endocrinol Metab 2005; 90(3): 1578–1582.
Marra F, Bertolani C. Adipokines in liver diseases. Hepatology 2009; 50(3): 957–969.
Miele L, Valenza V, La Torre G et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009; 49(6): 1877–1887.
Aron-Wisnewsky J, Vigliotti C, Witjes J et al. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol 2020; 17(5): 279–297.
Puri P, Daita K, Joyce A et al. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids. Hepatology 2017; 67(2): 534–548.
Vítek L, Haluzík M. The role of bile acids in metabolic regulation. J Endocrinol 2016; 228(3): R85–R96.
Bell LN, Theodorakis JL, Vuppalanchi R et al. Serum proteomics and biomarker discovery across the spectrum of nonalcoholic fatty liver disease. Hepatology 2009; 51(1): 111–120.
Williams CD, Stengel J, Asike MI et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011; 140(1): 124–131.
Ren TY, Fan JG. What are the clinical settings and outcomes of lean NAFLD? Nat Rev Gastroenterol Hepatol 2021; 18(5): 289–290.
Pingitore P, Romeo S. The role of PNPLA3 in health and disease. Biochim Biophys Acta Mol Cell Biol Lipids 2019; 1864(6): 900–906.
Willeit P, Skroblin P, Moschen AR et al. Circulating microRNA-122 is associated with the risk of new-onset metabolic syndrome and type 2 diabetes. Diabetes 2016; 66(2): 347–357.
Zhao Q, Qin CY, Zhao ZH et al. Epigenetic modifications in hepatic stellate cells contribute to liver fibrosis. Tohoku J Exp Med 2013; 229(1): 35–43.
Boström P, Wu J, Jedrychowski MP et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. Nature 2012; 481(7382): 463–468.
Simon TG, King LY, Chong DQ et al. Diabetes, metabolic comorbidities, and risk of hepatocellular carcinoma: Results from two prospective cohort studies. Hepatology 2018; 67(5): 1797–1806.
Eslam M, Newsome PN, Sarin SK et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol 2020; 73(1): 202–209.
Targher G, Byrne CD, Lonardo A et al. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: A meta-analysis. J Hepatol 2016; 65(3): 589–600.
Simon TG, Roelstraete B, Khalili H et al. Mortality in biopsy-confirmed nonalcoholic fatty liver disease: results from a nationwide cohort. Gut 2020; 70(7): 1375–1382.
Nobili V, Alisi A, Valenti L et al. NAFLD in children: new genes, new diagnostic modalities and new drugs. Nat Rev Gastroenterol Hepatol 2019; 16(9): 517–530.
Liu J, Mu C, Li K et al. Estimating global prevalence of metabolic dysfunction-associated fatty liver disease in overweight or obese children and adolescents: systematic review and meta-analysis. Int. J. Public Health 2021; 66.

Štítky

Addictology Allergology and clinical immunology Angiology Audiology Clinical biochemistry Dermatology & STDs Paediatric gastroenterology Paediatric surgery Paediatric cardiology Paediatric neurology Paediatric ENT Paediatric psychiatry Paediatric rheumatology Diabetology Pharmacy Vascular surgery Pain management Dental Hygienist

Článek ÚVODEM

Článek EDITORIAL

Článek Liver tests

Článek Diagnostic methods of fatty liver diseases

Článek Liver elastography

Článek Diagnosis of non-alcoholic fatty liver disease and its active screening in risk groups

Článek An overview of current therapy options of non-alcoholic fatty liver disease

Článek Statins and liver

Článek Alcohol-related liver disease in medical practice

Článek Current hepatitis C therapy

Článek Klinická obezitologie – nejen Základy

Článek Dietary habits in students from the medical faculties